Benralizumab, Mechanism of action, Drug Interactions, Therapeutic Uses, Adverse effects and Contraindications

Benralizumab

 Benralizumab is a monoclonal antibody medication used to treat severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps. It is sold under the brand name Fasenra.

Eosinophilic asthma is a type of asthma characterized by increased levels of eosinophils, a type of white blood cell, in the airways. These eosinophils can contribute to inflammation, leading to severe asthma symptoms and exacerbations. Benralizumab works by targeting and blocking the receptor for interleukin-5 (IL-5), a protein that plays a crucial role in the production and activation of eosinophils. By blocking this pathway, the drug reduces the number of eosinophils, which helps to decrease airway inflammation and improve asthma control.

Fasenra is administered as an injection under the skin (subcutaneously) once every four weeks for the first three doses and then once every eight weeks thereafter, making it a maintenance treatment for asthma.

Mechanism Of Action

The MOA (Mechanism of Action) of Benralizumab involves targeting and blocking the alpha subunit of the interleukin-5 receptor (IL-5Rα) on the surface of eosinophils, which are a type of white blood cell involved in allergic responses and inflammation. Here's a step-by-step breakdown of the mechanism:

1. Binding to IL-5 Receptor: Benralizumab is a monoclonal antibody that specifically binds to the alpha subunit of the interleukin-5 receptor (IL-5Rα) present on the surface of eosinophils.

2. Depletion of Eosinophils: Once bound to the IL-5 receptor on eosinophils, benralizumab triggers a process called antibody-dependent cell-mediated cytotoxicity (ADCC). This process involves immune cells, such as natural killer cells, recognizing and binding to the Fc (fragment crystallizable) portion of benralizumab, which is exposed after the antibody binds to the IL-5Rα on eosinophils.

3. Eosinophil Destruction: The immune cells that have bound to benralizumab through ADCC release substances that cause cell death (cytotoxicity) of the eosinophils. This process leads to the destruction and elimination of eosinophils from the bloodstream and tissues.

4. Reduction of Airway Inflammation: Eosinophils play a key role in causing inflammation in the airways of individuals with conditions like severe eosinophilic asthma. By depleting eosinophils, benralizumab helps reduce airway inflammation, leading to improved asthma control and fewer exacerbations in patients with severe eosinophilic asthma.

In summary, Benralizumab's MOA involves selectively targeting and depleting eosinophils through binding to the alpha subunit of the IL-5 receptor, which ultimately reduces airway inflammation and improves asthma symptoms in individuals with severe eosinophilic asthma.

Drug Interactions

Specific drug interactions with benralizumab have not been extensively documented in medical literature. However, as with any medication, it's essential to be cautious and aware of potential interactions, especially if you are taking other medications or have underlying medical conditions.

As benralizumab primarily targets eosinophils in the immune system, it is not expected to interact directly with other medications in the same way that traditional small-molecule drugs do. Nevertheless, the following general points should be considered:

1. Immunosuppressive Medications: Because benralizumab affects the immune system, caution should be exercised when using it alongside other immunosuppressive medications, as this may increase the risk of infections.

2. Vaccines: Benralizumab may interfere with the body's response to live or live-attenuated vaccines. It is essential to discuss the timing of vaccinations with your healthcare provider, especially if you require any immunizations while receiving benralizumab treatment.

3. Other Asthma Medications: If you are taking other medications for asthma management, such as inhaled corticosteroids or long-acting beta-agonists, your healthcare provider will consider the overall treatment plan to ensure the combination is safe and effective.

4.  Biologic medications: As benralizumab is a biologic agent, it should be used with caution alongside other biologic medications to avoid potential additive effects or unknown interactions.

Therapeutic Uses

Benralizumab (Fasenra) is primarily used for the following therapeutic indications:

1. Severe Eosinophilic Asthma: Benralizumab is approved for the treatment of severe eosinophilic asthma in adults and children aged 12 years and older. Eosinophilic asthma is a subtype of asthma characterized by elevated levels of eosinophils in the airways, leading to increased inflammation and more severe symptoms. Benralizumab helps to reduce airway inflammation by depleting eosinophils, thereby improving asthma control and reducing the frequency of asthma exacerbations.

2. chronic Rhinosinusitis: In addition to its use in asthma, benralizumab is also approved for the treatment of chronic rhinosinusitis with nasal polyps in adults aged 18 years and older. Chronic rhinosinusitis is a condition characterized by inflammation of the sinuses and nasal passages, often accompanied by the growth of nasal polyps. Benralizumab can help reduce the size of nasal polyps and improve symptoms in patients with this condition.

It's important to note that benralizumab is not used to provide immediate relief for acute asthma attacks or as a rescue medication. Instead, it is considered a maintenance treatment for individuals with severe eosinophilic asthma who have not adequately responded to other asthma medications.

Side Effects

Benralizumab (Fasenra) is generally well-tolerated, but like any medication, it may cause side effects in some individuals. Common and potentially serious side effects associated with benralizumab can include:

1. Injection Site Reactions: Redness, pain, swelling, or itching at the injection site can occur. These reactions are usually mild and resolve on their own.

2. Hypersensitivity Reactions: Some individuals may experience allergic reactions to benralizumab, which can range from mild symptoms like rash, itching, or hives to more severe reactions such as difficulty breathing, swelling of the face, lips, tongue, or throat (angioedema), or anaphylaxis (a severe, life-threatening allergic reaction). Patients should seek immediate medical attention if they experience signs of a severe allergic reaction.

3. Upper Respiratory Tract Infections: Some patients may experience common cold-like symptoms, such as nasal congestion, sore throat, or sinusitis.

4. Headache: Headache is a possible side effect reported by some individuals receiving benralizumab treatment.

5. Fatigue: Some patients may experience fatigue or tiredness.

6. Gastrointestinal Disorders: Nausea, diarrhea, or stomach pain may occur in some cases.

It's important to remember that not all patients will experience these side effects, and many individuals tolerate benralizumab well without any significant adverse effects.

Contraindications

Specific contraindications for benralizumab (Fasenra) have not been widely documented in medical literature. However, as with any medication, there may be certain situations or medical conditions where the use of benralizumab is not recommended or should be approached with caution.

Here are some general situations where caution or further evaluation may be necessary:

1. Hypersensitivity or Allergy: If you have a known hypersensitivity or allergy to benralizumab or any of its components, its use should be avoided.

2. Immunosuppression: Individuals with severe immunosuppression, such as those with advanced human immunodeficiency virus (HIV) infection or taking high-dose immunosuppressive medications, may have an increased risk of infections with benralizumab treatment.

3. Active Infections: Benralizumab may increase the risk of infections. If you have an active infection or a history of recurrent infections, your healthcare provider may assess whether it is appropriate to initiate or continue benralizumab treatment.

4. Pregnancy and Breastfeeding: The safety of benralizumab during pregnancy and breastfeeding has not been well-established. If you are pregnant, planning to become pregnant, or breastfeeding, discuss the risks and benefits with your healthcare provider.

5. Live Vaccines: Avoid receiving live or live-attenuated vaccines while on benralizumab treatment, as this type of immunization may not be as effective and could pose risks.

6. Children and Adolescents: Safety and effectiveness of benralizumab in children under 12 years of age have not been fully established.